King Fahd University of Petroleum and Minerals

Jin Gohda

Mahmoud Elsayed

Yasushi Kawaguchi

Abdulla Yousef Al-Taher

Hyung-Joo Kwon

Mizuki Yamamoto

Jun-Ichiro Inoue

Anti-SARS-CoV-2 fusion peptides are provided. The anti-SARS-CoV-2 fusion peptides include peptide sequences corresponding to the sequence of the SARS-CoV-2 fusion complex heptad repeat domain HR2 and having at least one artificial mutation. The anti-SARS-CoV-2 fusion peptides may be 39-mers, such as peptides #121 (SEQ ID NO: 2) and #125 (SEQ ID NO: 5). These peptides may competitively bind to SARS-CoV-2 and prevent either membrane mediated SARS-CoV-2 fusion, endocytosis-mediated viral entry, or both. The anti-SARS-CoV-2 fusion peptides may be administered to a subject in need thereof to inhibit or prevent SARS-CoV-2 cellular entry.

Growing community of inventors

Kanagawa, Japan

Jin Gohda